ProAxsis who leverages their proprietary protease-targeted technology and NEATstik platform to address unmet needs in chronic respiratory disease diagnostics, has increased revenues and decreased losses. There is a strong sales pipeline, including provisional orders; as well as advanced plans for a clinical study in Chronic Obstructive Pulmonary Disease (COPD) in partnership with Imperial College London, targeted at expanding clinical trials. Additionally, the Company continues to have benefit from Grant Funding.
Ilian Iliev, CEO of EMVC PLC, commented:
“During 2024, ProAxsis made significant progress in stabilising the business platform, advancing its commercial development and progressing its clinical trials plans for the COPD space. Through our value creation services programme, EMV Capital helped ProAxsis evolve to a leaner and more focused business. The company is in a good position to enter the next stage of its development. The current fundraise is aimed at delivering critical clinical milestones, commercial traction, and significant future value creation and we look forward to continuing to work alongside ProAxsis to achieve these.”
To read more about the fundraising and ProAxsis’s progress, click here.